Effient (Prasugrel)
Indications
Prasugrel is a third-generation thienopyridine P2Y12 antagonist with a single FDA indication: reduction of thrombotic cardiovascular events — including stent thrombosis — in patients with acute coronary syndrome who are managed with percutaneous coronary intervention. Unlike ticagrelor, the approved use is narrowly tied to PCI; trials in medically managed acute coronary syndromes (TRILOGY-ACS) and in pretreatment before angiography (ACCOAST) were negative.
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Unstable angina or NSTEMI managed with PCI | Adults; coronary anatomy known before loading dose (per FDA PI) | Adjunctive to aspirin | FDA Approved |
| STEMI managed with primary or delayed PCI | Adults presenting within 12 h (loading at diagnosis) or 12 h–14 d (after angiography) | Adjunctive to aspirin | FDA Approved |
| Genotype-guided P2Y12 escalation in clopidogrel CYP2C19 loss-of-function carriers | Post-PCI patients with confirmed CYP2C19 LOF alleles | Substitution for clopidogrel | Off-label |
| De-escalation strategy — switch from ticagrelor in chronic phase | Post-ACS, stable phase, intolerance to ticagrelor (e.g., dyspnoea) | Switch antiplatelet | Off-label |
The pivotal evidence is TRITON-TIMI 38 (Wiviott 2007), in which 13,608 patients with ACS planned for PCI were randomised to prasugrel (60 mg load, 10 mg daily) or clopidogrel (300 mg load, 75 mg daily). The primary composite of cardiovascular death, non-fatal MI, or non-fatal stroke was 9.3% vs 11.2% in the UA/NSTEMI cohort and 9.8% vs 12.2% in the STEMI cohort, both favouring prasugrel; stent thrombosis fell by approximately 50%. The benefit was driven almost entirely by reduction in non-fatal MI, with no difference in cardiovascular mortality. ISAR-REACT 5 (Schüpke 2019) subsequently showed prasugrel superior to ticagrelor on the composite ischaemic endpoint in ACS patients undergoing planned invasive evaluation, with no excess of major bleeding (BARC 3–5 5.4% ticagrelor vs 4.8% prasugrel).
Genotype-guided escalation (moderate-quality evidence): POPular Genetics and TAILOR-PCI evaluated CYP2C19-guided P2Y12 selection after PCI. Switching from clopidogrel to prasugrel (or ticagrelor) in carriers of loss-of-function alleles is endorsed as a Class IIb recommendation in the 2021 ACC/AHA/SCAI revascularisation guideline.
De-escalation from ticagrelor (low-to-moderate quality): TROPICAL-ACS supported guided de-escalation strategies after the acute phase. Switching from ticagrelor to prasugrel (rather than clopidogrel) is occasionally used when ticagrelor-related dyspnoea limits adherence but ischaemic risk remains high.
Dosing
Prasugrel dosing is unusually weight-aware for an antiplatelet agent: patients under 60 kg may receive a reduced 5 mg maintenance dose because of substantially higher exposure to the active metabolite and increased bleeding risk in TRITON-TIMI 38. The 60 mg loading dose is used in all weight categories. Once-daily dosing simplifies adherence compared with twice-daily ticagrelor.
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| STEMI, primary PCI within 12 h of symptom onset | 60 mg PO load at diagnosis | 10 mg PO daily | 10 mg daily | Co-administer with ASA 75–325 mg Most patients in TRITON-TIMI 38 received the load at the time of PCI |
| STEMI presenting 12 h–14 d, delayed PCI | 60 mg PO load after angiography | 10 mg PO daily | 10 mg daily | Defer load until coronary anatomy known |
| UA / NSTEMI managed with PCI | 60 mg PO load at PCI | 10 mg PO daily | 10 mg daily | Pretreatment before angiography is not recommended (ACCOAST: no benefit, increased bleeding) |
| Body weight <60 kg | 60 mg PO load (unchanged) | 5 mg PO daily (consider) | 5 mg daily | 5 mg dose not prospectively validated for efficacy AUC of active metabolite ~30–40% higher in low-weight patients |
| STEMI / NSTEMI on ticagrelor or clopidogrel — switch to prasugrel | 60 mg load 24 h after last ticagrelor dose; can switch from clopidogrel without interruption | 10 mg daily (or 5 mg if <60 kg) | 10 mg daily | Do not administer prasugrel during cangrelor infusion (cangrelor blocks prasugrel binding) |
Special populations
| Population | Adjustment | Rationale |
|---|---|---|
| Age ≥75 years | Generally not recommended | Increased fatal bleeding (1.0% vs 0.1% clopidogrel) and ICH (0.8% vs 0.3%) in TRITON-TIMI 38; consider only if diabetes or prior MI present and a clear benefit anticipated |
| Body weight <60 kg | Consider 5 mg daily maintenance | Higher active-metabolite exposure; non-CABG bleeding 10.1% vs 6.5% clopidogrel on 10 mg dose |
| Renal impairment (any stage) | No adjustment needed | PK of active metabolite similar in moderate impairment; ESRD exposure is approximately half that of healthy controls but bleeding risk is generally higher |
| Mild to moderate hepatic impairment (Child-Pugh A/B) | No adjustment | PK and platelet inhibition similar to healthy subjects |
| Severe hepatic impairment (Child-Pugh C) | Not studied; use with caution given general bleeding risk | No PK/PD data; FDA PI does not list as a contraindication but flags higher bleeding risk |
| Paediatric (<18 years) | Not established | Sickle cell anaemia trial in 2–17-year-olds did not meet primary endpoint of vaso-occlusive crisis reduction |
| CYP2C19 loss-of-function carriers | No adjustment; may be preferred over clopidogrel | Prasugrel’s active metabolite formation is independent of CYP2C19 genotype (FDA PI 8.9, 12.5) |
• Hold for 7 days before any elective surgery, including CABG — the highest-risk window for bleeding (FDA PI). Withholding a single dose is ineffective because platelet inhibition is irreversible for the platelet’s lifespan.
• Do not start prasugrel if urgent CABG is likely. CABG-related TIMI major or minor bleeding was 14.1% vs 4.5% with clopidogrel in TRITON-TIMI 38.
• Do not split or crush tablets routinely — the FDA PI explicitly warns against breaking tablets. Crushed administration has been studied for faster onset in primary PCI but is not in the approved labelling.
• Aspirin 75–325 mg is the FDA-labelled co-medication; low-dose ASA (81–100 mg) is preferred in current practice.
• Cangrelor blocks prasugrel binding when given together. Wait until the cangrelor infusion is complete before administering the prasugrel loading dose.
Pharmacology
Mechanism of Action
Prasugrel is a thienopyridine prodrug that produces irreversible inhibition of platelet activation and aggregation through covalent binding of its active metabolite to the platelet P2Y12 ADP receptor. Two features distinguish it from clopidogrel, the older thienopyridine. First, prasugrel undergoes a more efficient single-step CYP-mediated activation: after rapid intestinal hydrolysis to a thiolactone intermediate, conversion to the active metabolite occurs primarily through CYP3A4 and CYP2B6 (with smaller contributions from CYP2C9 and CYP2C19). Clopidogrel, in contrast, requires two sequential CYP steps with substantial CYP2C19 dependence. Second, prasugrel’s pharmacokinetics and platelet inhibition are not affected by CYP2C19 loss-of-function alleles — a critical advantage in the roughly 30% of patients with reduced clopidogrel responsiveness. Onset is rapid: approximately 90% of patients achieve at least 50% inhibition of platelet aggregation within 1 hour of a 60 mg loading dose, with peak inhibition near 80%. Steady-state inhibition on 10 mg daily averages around 70%, and platelet function recovers over 5–9 days after discontinuation, paralleling new platelet production rather than drug clearance.
ADME profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | ≥79% absorbed; active metabolite Tmax ~30 min; high-fat meal decreases Cmax 49% and delays Tmax to 1.5 h but does not change AUC | Faster onset than clopidogrel; food does not impair overall exposure but may delay effect in primary PCI |
| Distribution | Apparent Vd of active metabolite 44–68 L; protein binding ~98% (active metabolite) | Limited extravascular distribution; unlikely to cause clinically important protein-displacement interactions |
| Metabolism | Prasugrel itself is undetectable in plasma after dosing; rapid intestinal hydrolysis → thiolactone → active metabolite (CYP3A4 and CYP2B6 primary; CYP2C9 and CYP2C19 minor) | CYP2C19 genotype does not meaningfully affect activity; most CYP3A inhibitors and inducers do not alter PK significantly |
| Elimination | Active metabolite t½ ~7 h (range 2–15 h); ~68% urine and ~27% faecal excretion (as inactive metabolites); apparent clearance 112–166 L/h | No renal dose adjustment; active metabolite not effectively dialysable; platelet recovery over 5–9 days driven by new platelet production |
Roughly 30% of Caucasians and a higher proportion of East Asians carry CYP2C19 loss-of-function alleles, reducing clopidogrel’s active metabolite formation. The FDA PI for prasugrel notes there is no relevant effect of genetic variation in CYP2B6, CYP2C9, CYP2C19, or CYP3A5 on prasugrel’s active metabolite or platelet inhibition. Combined with concomitant proton-pump inhibitor use (which inhibits CYP2C19 and was widespread in TRITON-TIMI 38), this pharmacogenomic difference is the leading mechanistic explanation for prasugrel’s greater treatment effect — and its greater bleeding rate — relative to clopidogrel.
Side Effects
All frequency data below are drawn from the FDA prescribing information, which is based on TRITON-TIMI 38 (n=6,741 prasugrel-treated patients; median 14.5 months). Comparators are clopidogrel-treated patients from the same trial unless otherwise noted. Bleeding rates differ markedly by patient subgroup — weight under 60 kg, age over 75, and CABG within 7 days of last dose all substantially increase risk.
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| CABG-related TIMI major or minor bleeding (in patients undergoing CABG) | 14.1% vs 4.5% clopidogrel | Substantial bleeding risk in any patient who proceeds to CABG within 7 days of dosing Within 3 days of last dose: 26.7% vs 5.0% (TRITON-TIMI 38) |
| Non-CABG bleeding in body weight <60 kg subgroup | 10.1% vs 6.5% clopidogrel | One of the principal indications for the 5 mg maintenance dose |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Hypertension | 7.5% vs 7.1% clopidogrel | Likely reflects underlying CV comorbidity rather than drug effect |
| Hypercholesterolaemia / hyperlipidaemia | 7.0% vs 7.4% | Reflects population characteristics |
| Epistaxis | 6.2% vs 3.3% clopidogrel | Most frequent specifically reported bleeding adverse reaction |
| Headache | 5.5% vs 5.3% | Generally mild; rarely dose-limiting |
| Back pain | 5.0% vs 4.5% | Common in post-PCI population |
| Dyspnoea | 4.9% vs 4.5% | Rate similar to clopidogrel; not the off-target dyspnoea seen with ticagrelor |
| Nausea | 4.6% vs 4.3% | Take with or without food |
| Non-CABG TIMI major or minor bleeding (overall) | 4.5% vs 3.4% | Risk highest in the first week after loading |
| Dizziness | 4.1% vs 4.6% | Consider orthostatic vitals; may be multifactorial |
| Cough | 3.9% vs 4.1% | Not increased over clopidogrel |
| Hypotension | 3.9% vs 3.8% | Suspect occult bleeding in any patient who is hypotensive after recent procedure (FDA PI) |
| Atrial fibrillation | 2.9% vs 3.1% | Reflects baseline cardiovascular risk |
| Bradycardia | 2.9% vs 2.4% | Common in post-MI population on beta-blockers |
| Anaemia | 2.2% vs 2.0% | Investigate for occult bleeding; haemoglobin should be tracked |
| Diarrhoea | 2.3% vs 2.6% | Generally mild; not increased over clopidogrel |
| GI haemorrhage | 1.5% vs 1.0% | Add PPI in patients with GI bleeding risk factors |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Non-CABG TIMI major bleeding | 2.2% vs 1.7% clopidogrel | Risk highest in first 7 days | Manage without discontinuing if possible (FDA PI); consider platelet transfusion (note: ineffective within 6 h of load or 4 h of maintenance dose) |
| Life-threatening bleeding (non-CABG) | 1.3% vs 0.8% | Throughout therapy | Resuscitation; platelet transfusion outside loading window; ICU level care |
| Symptomatic intracranial haemorrhage | 0.3% vs 0.3% (overall); 0.8% vs 0.3% in age ≥75 | Throughout therapy | Permanent discontinuation; emergency neuroimaging; neurosurgical input |
| Fatal bleeding (non-CABG) | 0.3% vs 0.1% (overall); 1.0% vs 0.1% in age ≥75 | Any time | Resuscitation; root-cause review (mistimed elective surgery, contraindication missed) |
| CABG-related TIMI major bleeding | 11.3% vs 3.6% | Within 7 days of last dose | Hold drug 7 days before elective surgery; do not initiate if urgent CABG anticipated |
| Thrombotic thrombocytopenic purpura (TTP) | Rare (postmarketing reports) | Often within 2 weeks of starting | Discontinue immediately; haematology consult; urgent plasma exchange (life-threatening) |
| Hypersensitivity / anaphylaxis / angioedema | 0.06% angioedema; postmarketing anaphylaxis | Hours to days; cross-reactivity with other thienopyridines reported | Permanent discontinuation; switch to chemically unrelated agent (ticagrelor) |
| Severe thrombocytopenia | 0.06% vs 0.04% | Variable | Discontinue; rule out TTP and HIT; haematology referral |
| Newly diagnosed malignancy (signal in TRITON-TIMI 38) | 1.6% vs 1.2% (predominantly colon and lung) | During therapy | Causality unclear; FDA PI notes possible detection bias from bleeding investigations; maintain age-appropriate cancer screening |
| Reason for discontinuation | Incidence | Context |
|---|---|---|
| Bleeding (any) | 2.5% vs 1.4% | Predominant driver; risk highest in first 7 days; further elevated in age ≥75 and weight <60 kg subgroups |
| Allergic/hypersensitivity reactions | 0.36% (similar to clopidogrel) | Cross-reactivity with other thienopyridines reported; switch to ticagrelor if needed |
| Other non-haemorrhagic events | Variable (rash, GI intolerance, abnormal LFTs) | Usually permits switch to another antiplatelet agent without recurrence |
Three populations had disproportionate bleeding risk in TRITON-TIMI 38: patients with prior TIA or stroke (subgroup analysis showed net harm; now a contraindication), patients aged ≥75 (fatal bleeding 1.0% vs 0.1%; ICH 0.8% vs 0.3%; “generally not recommended”), and patients weighing <60 kg (non-CABG bleeding 10.1% vs 6.5%; consider 5 mg dose). The FDA PI advises suspecting bleeding in any post-procedure patient with hypotension — the most clinically important sign of occult haemorrhage in this population.
Drug Interactions
Prasugrel’s clinically meaningful interactions are dominated by additive bleeding from co-administered antithrombotics rather than CYP-mediated pharmacokinetic effects. Per the FDA PI, prasugrel can be administered with most CYP3A inhibitors (including ketoconazole, clarithromycin, diltiazem, verapamil) and inducers (rifampin, carbamazepine) without dose adjustment — ketoconazole reduces Cmax of the active metabolite by 34–46% but does not affect AUC or platelet inhibition. Genetic variation in CYP2C19, CYP2B6, CYP2C9, and CYP3A5 also has no clinically relevant effect.
Prasugrel’s metabolic pathway uses CYP3A4 and CYP2B6 efficiently in a single activation step, with minor CYP2C19 contribution. Because of this, prasugrel is largely insensitive to PPIs (which inhibit CYP2C19), to CYP2C19 genotype, and to CYP3A modulation in clinical practice. The corollary is that the major interactions are pharmacodynamic (additive bleeding from anticoagulants, NSAIDs, fibrinolytics) rather than pharmacokinetic.
Monitoring
Routine therapeutic drug monitoring is not used. Bedside platelet function tests (VerifyNow, Multiplate) are not recommended for routine prasugrel management — trials including TROPICAL-ACS, ARCTIC, and ANTARCTIC have not supported tailoring therapy by platelet reactivity outside research protocols. The principal clinical monitoring task is detecting bleeding early.
-
Bleeding signs & symptoms
Every visit; daily during inpatient
Routine Ask about bruising, gingival bleeding, epistaxis, melena, haematuria. Inspect mucous membranes. Suspect bleeding in any post-PCI/post-CABG patient who becomes hypotensive (FDA PI). Reinforce when to seek emergency care. -
Haemoglobin / haematocrit
Baseline; daily during admission; trigger-based outpatient
Trigger-based Recheck for unexplained fatigue, dyspnoea, drop in BP, or visible bleeding. Occult GI loss is the commonest cause of asymptomatic anaemia on DAPT. -
Platelet count
Baseline; with new bruising or neurological symptoms
Trigger-based TTP can occur within 2 weeks of starting prasugrel and is life-threatening; check urgently if pentad features (microangiopathic haemolytic anaemia, thrombocytopenia, neurological signs, renal dysfunction, fever) develop. Heparin-induced thrombocytopenia screening if recent heparin exposure. -
Renal function (eGFR, creatinine)
Baseline, then annually
Routine No dose adjustment for any renal stage, but ESRD patients are generally at higher bleeding risk; weigh ongoing benefit-risk in declining renal function. -
Body weight
Baseline, then with significant changes
Routine Crossing the 60 kg threshold (in either direction) should prompt a dose review. The 5 mg dose is an option in patients persistently <60 kg. -
Liver function (AST, ALT)
Baseline, then with symptoms
Trigger-based Abnormal hepatic function in 0.22% in TRITON-TIMI 38 (similar to clopidogrel). Recheck if jaundice, abdominal pain, or unexplained fatigue. -
Cancer screening
Per age-appropriate guideline
Routine TRITON-TIMI 38 reported a small numerical excess of newly diagnosed malignancies (1.6% vs 1.2%, predominantly colon and lung). Causality is unclear; FDA PI suggests detection bias is plausible. Maintain colorectal and lung cancer screening per population recommendations. -
Adherence assessment
Every visit
Routine Once-daily dosing supports adherence relative to ticagrelor. Use pill counts, refill data, or patient-reported missed doses. Premature discontinuation is the largest preventable cause of stent thrombosis on DAPT. -
Bleeding risk reassessment (PRECISE-DAPT, DAPT score)
At 6 and 12 months post-ACS
Routine Drives decisions on duration extension, de-escalation, or shortening of DAPT. Integrate with ischaemic risk (e.g., complex PCI, multi-vessel disease, recurrent events).
Hold prasugrel for 7 days before any elective surgery, including CABG (FDA PI). For urgent CABG within 7 days of last dose, expect substantial bleeding (TIMI major or minor 14.1% vs 4.5% with clopidogrel). Platelet transfusion may restore haemostasis but is unlikely to be effective within 6 hours of the loading dose or 4 hours of the maintenance dose, because circulating active metabolite will inhibit transfused platelets. There is no specific reversal agent for prasugrel; the active metabolite is not effectively dialysable.
Contraindications & Cautions
Effient can cause significant, sometimes fatal, bleeding. Do not use Effient in patients with active pathological bleeding or a history of transient ischaemic attack or stroke. In patients aged 75 years or older, Effient is generally not recommended, except in high-risk patients (diabetes or prior MI) where its use may be considered. Do not start Effient in patients likely to undergo urgent CABG; when possible, discontinue Effient at least 7 days before any surgery.
Additional risk factors for bleeding include body weight under 60 kg, propensity to bleed, and concomitant medications that increase bleeding risk (e.g., warfarin, heparin, fibrinolytic therapy, chronic NSAID use). Suspect bleeding in any patient who is hypotensive after recent invasive or surgical procedures. If possible, manage bleeding without discontinuing Effient — stopping the drug increases the risk of subsequent cardiovascular events.
Absolute contraindications (FDA prescribing information, Section 4)
- Active pathological bleeding (e.g., active peptic ulcer haemorrhage, intracranial haemorrhage)
- History of transient ischaemic attack (TIA) or stroke — ischaemic or haemorrhagic, at any time. In TRITON-TIMI 38, prior TIA/stroke patients had a stroke rate of 6.5% on prasugrel vs 1.2% on clopidogrel
- Hypersensitivity to prasugrel or any excipient (anaphylaxis, angioedema). Cross-reactivity with other thienopyridines (clopidogrel, ticlopidine) has been reported
Generally not recommended (FDA boxed warning)
- Age ≥75 years — except in high-risk subgroups: use may be considered in patients with diabetes or prior MI where the benefit-risk balance is more favourable; for all other elderly patients, prefer clopidogrel or ticagrelor
- Patients likely to undergo urgent CABG: do not initiate
- Within 7 days of any planned surgery with major bleeding risk
Relative contraindications — specialist input recommended
- Body weight <60 kg: consider 5 mg maintenance dose; bleeding risk on the 10 mg dose was substantially elevated in TRITON-TIMI 38
- Severe hepatic impairment (Child-Pugh C): not studied; bleeding risk likely higher
- End-stage renal disease on dialysis: limited data; generally higher bleeding risk in this population
- Concomitant oral anticoagulation: 2023 ESC ACS guideline favours clopidogrel over prasugrel in patients requiring concurrent OAC for AF or other indications; minimise duration of triple therapy
- NSTEMI before coronary anatomy is known (pretreatment): ACCOAST showed no benefit and increased bleeding from pre-angiography loading; defer until PCI is confirmed
- Recent fibrinolytic therapy: avoid <24 h after tPA-class agents and <48 h after streptokinase (per TRITON-TIMI 38 protocol)
- Pregnancy: no human data; reserve for situations where benefit clearly outweighs risk
- Lactation: no human data; metabolites detected in rat milk; discuss benefit-risk with the mother
Use with caution
- Recent or recurrent GI bleeding, active peptic ulcer disease: treat H. pylori, optimise PPI, reassess net benefit
- Recent trauma or surgery within prior weeks: weigh bleeding risk against ischaemic protection
- Concomitant SSRI/SNRI or chronic NSAID use: add PPI; reassess GI bleeding risk factors
- Planned spinal or epidural anaesthesia: risk of spinal haematoma; coordinate with anaesthesia
- Severe asthma/COPD: not specifically a prasugrel concern (unlike ticagrelor) but may complicate management of bleeding-related dyspnoea
Patient Counselling
Purpose of therapy
Explain that prasugrel is a blood-thinning medicine that reduces the risk of another heart attack, blood clot in the stent, or death from cardiovascular causes after acute coronary syndrome treated with stenting. It works by stopping platelets from clumping together at the site of damaged blood vessels. It is taken together with low-dose aspirin — this combination is called dual antiplatelet therapy (DAPT). Stopping prasugrel too early is one of the most common causes of stent thrombosis, a life-threatening blockage of a stent. Patients should never stop the drug without speaking to their cardiologist first.
How to take
Prasugrel is taken once daily, with or without food, ideally at the same time each day. Tablets must not be split, broken, or crushed (FDA PI). If a dose is missed, take it as soon as remembered — but if it is almost time for the next dose, skip the missed dose and take the next dose at the regular time. Doses are never doubled. Continue low-dose aspirin (75–100 mg) every day. The course duration depends on stent type, ischaemic risk, and bleeding risk — typically 12 months after ACS, with possible extension or de-escalation thereafter. Bring a list of all medicines, including over-the-counter products and herbal remedies, to every clinic visit. Keep tablets in the original container with the desiccant.
Sources
- U.S. Food and Drug Administration. EFFIENT (prasugrel) tablets — Prescribing Information (revised 12/2020). accessdata.fda.gov/drugsatfda_docs/label/2020/022307s018lbl.pdf Primary regulatory source for indications, dosing, boxed warning, contraindications, adverse-reaction frequencies, and interaction studies.
- European Medicines Agency. Efient (prasugrel) Summary of Product Characteristics. ema.europa.eu/en/medicines/human/EPAR/efient European prescribing reference; useful for dosing nuances and additional warnings.
- U.S. FDA. Drugs@FDA database, Effient (prasugrel) approval history. accessdata.fda.gov/scripts/cder/daf/ Tracks labelling changes since the original July 2009 approval.
- Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes (TRITON-TIMI 38). N Engl J Med. 2007;357(20):2001-2015. doi.org/10.1056/NEJMoa0706482 Pivotal randomised trial — basis for the FDA approval and the comparative effectiveness/safety benchmarks against clopidogrel.
- Schüpke S, Neumann FJ, Menichelli M, et al. Ticagrelor or prasugrel in patients with acute coronary syndromes (ISAR-REACT 5). N Engl J Med. 2019;381(16):1524-1534. doi.org/10.1056/NEJMoa1908973 Investigator-initiated head-to-head trial showing prasugrel superior to ticagrelor on composite ischaemic endpoint without an excess of major bleeding.
- Roe MT, Armstrong PW, Fox KAA, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization (TRILOGY ACS). N Engl J Med. 2012;367(14):1297-1309. doi.org/10.1056/NEJMoa1205512 Negative trial in medically managed NSTE-ACS — defines the boundary of prasugrel’s evidence-supported use.
- Montalescot G, Bolognese L, Dudek D, et al. Pretreatment with prasugrel in non–ST-segment elevation acute coronary syndromes (ACCOAST). N Engl J Med. 2013;369(11):999-1010. doi.org/10.1056/NEJMoa1308075 Showed no efficacy benefit and increased bleeding from pretreatment in NSTE-ACS — supports administering the loading dose at PCI.
- Savonitto S, Ferri LA, Piatti L, et al. Comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization (Elderly ACS 2). Circulation. 2018;137(23):2435-2445. doi.org/10.1161/CIRCULATIONAHA.117.032180 Tested low-dose (5 mg) prasugrel vs clopidogrel in elderly ACS-PCI patients; trial halted early without efficacy benefit and with bleeding signal.
- Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720-3826. doi.org/10.1093/eurheartj/ehad191 Current European recommendations on P2Y12 selection, DAPT duration, and patient-specific choices among prasugrel, ticagrelor, and clopidogrel.
- Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization. J Am Coll Cardiol. 2022;79(2):e21-e129. doi.org/10.1016/j.jacc.2021.09.006 US revascularisation guidance addressing P2Y12 selection, DAPT after PCI, and genotype-guided strategies.
- Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA Guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease. J Am Coll Cardiol. 2016;68(10):1082-1115. doi.org/10.1016/j.jacc.2016.03.513 Foundation document for DAPT duration decisions and de-escalation strategies; still cited extensively in practice.
- Brandt JT, Payne CD, Wiviott SD, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J. 2007;153(1):66.e9-66.e16. doi.org/10.1016/j.ahj.2006.10.010 Establishes the more efficient and consistent active-metabolite formation that underlies prasugrel’s pharmacodynamic advantage over clopidogrel.
- Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360(4):354-362. doi.org/10.1056/NEJMoa0809171 Foundational paper on CYP2C19 loss-of-function alleles affecting clopidogrel — the pharmacogenomic basis for preferring prasugrel in known LOF carriers.
- Small DS, Farid NA, Payne CD, et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol. 2008;48(4):475-484. doi.org/10.1177/0091270008315310 Underpins the FDA PI position that PPIs do not meaningfully impair prasugrel activity, in contrast to clopidogrel.
- Riesmeyer JS, Salazar DE, Weerakkody GJ, et al. Relationship between exposure to prasugrel active metabolite and clinical outcomes in the TRITON-TIMI 38 substudy. J Clin Pharmacol. 2012;52(6):789-797. doi.org/10.1177/0091270011406280 Defines the exposure-response relationships that justify the 5 mg dose recommendation in patients <60 kg.